About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Ribociclib Plus Hormone Therapy Benefits Hormone Receptor-positive Breast Cancer Patients

by Colleen Fleiss on June 1, 2019 at 10:01 PM
Font : A-A+

Ribociclib Plus Hormone Therapy Benefits Hormone Receptor-positive Breast Cancer Patients

Ribociclib plus hormone therapy was found to extend survival for patients with premenopausal advanced hormone receptor-positive breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

The combination resulted in 70.2 percent OS at 42 month follow up compared to just 46 percent OS in patients receiving hormone therapy plus placebo. This corresponds to a 29 percent lower risk of death in patients receiving the combination therapy. The authors also reported no new side effects than those previously described. This is the first demonstration of a survival advantage from the addition of a biological therapy to hormonal therapy.

Advertisement


The trial results published this month in the New England Journal of Medicine and will be presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. The current results build upon the primary endpoint data previously reported at the 2017 San Antonio Breast Cancer Symposium and published in Lancet Oncology.

"The data from MONALEESA-7 provide clear evidence that ribociclib offers a significant survival advantage compared to hormone therapy alone in premenopausal patients," said senior author Debu Tripathy, M.D., chair of Breast Medical Oncology. "Breast cancer in younger women is known to be more aggressive and have distinct genetic changes compared to postmenopausal patients, so this provides a much-needed therapeutic option for these patients."
Advertisement

Ribociclib is one of a class of drugs that inhibit cyclin-dependent kinases 4/6 (CDK4/6), proteins necessary for progression of the cell cycle. In 2018, ribociclib became the first CDK 4/6 inhibitor approved by the Food and Drug Administration for treatment of premenopausal patients with advanced HR+ breast cancer in combination with hormone therapies.

The international, randomized Phase III clinical trial enrolled 672 metastatic breast cancer patients, all of whom were pre- or peri-menopausal (ceased having periods within the last year) at diagnosis with HR+, HER2-negative disease. Participants could not have had prior hormone therapy for advanced disease or more than one cycle of chemotherapy for advanced disease.

Patients were randomized to receive either ribociclib (335) or placebo (337) in combination with tamoxifen or a nonsteroidal aromatase inhibitor (NSAI), and goserelin, an ovarian suppression drug. In the ribociclib arm, 87 patients (26 percent) received tamoxifen, compared with 90 patients (26.7 percent) in the placebo arm.

The median duration of treatment with ribociclib was approximately two years, which is eight months longer than it was at the time of primary analysis of progression-free survival. No new toxic effect emerged with the longer follow-up. The most common adverse event was neutropenia, which occurred in 63.5 percent of patients in the ribociclib group compared to 4.5 percent of patients in the placebo arm. Hepatobiliary toxic effects occurred in 11 percent and 6.8 percent respectively.

"This study confirms the benefits of these drugs are similar in both pre- and post-menopausal patients with advanced hormone receptor-positive breast cancers, and it further validates the clinical value of adding ribociclib for these patients," said Tripathy.

Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Category
What's New on Medindia
Ten Fruits for Diabetics
Natural Supplements Help Reverse Hair Loss during Menopause
Ways to Manage Stress during COVID-19 Pandemic
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Women and Cancer Breast Biopsy Pagets disease of the breast Mastitis Cancer and Homeopathy Reiki and Pranic Healing Breast Cancer Facts Cancer Facts Cancer Tattoos A Body Art 

Recommended Reading
Breast Cancer Management: Advances
The crab that invades the breast is no more a fear factor with all the advancements that medical ......
Quiz on Breast Cancer
Breast cancer is one of the leading causes of cancer deaths among women. It is often said that a ......
Breast Cancer Risk Assessment Calculator
Breast Cancer Risk Assessment Calculator predicts the risk for breast cancer. Find list of breast .....
Clinical Calculator Could Spare Breast Cancer Patients Five Years of Unnecessary Hormone Therapy, Says Study
CTS5 algorithm was found to accurately identify patients who are at a significantly low risk of ......
Breast Biopsy
Breast biopsy involves removing a sample of breast tissue to determine whether it is cancerous or .....
Mastitis
Mastitis is a common cause of tenderness, swelling and pain in breast, owing to inflammation in the ...
Pagets disease of the breast
A detailed description of the Paget's disease of the breast, characteristic signs and symptoms, dete...
Tattoos A Body Art
Tattoos are a rage among college students who sport it for the ‘cool dude’ or ‘cool babe’ look...
Women and Cancer
Cancer is one of the frequently talked about and most feared disease that falls under the genre of l...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use